A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524008-32-00

Enrollment

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capecitabine-induced hand and foot syndrome

Brief summary

Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events

Detailed description

Incidence and severity of NCI-CTCAE (Palmar-plantar erythrodysesthesia syndrome) grading by oncologist

Interventions

DRUGTAR-0520 Gel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events	—

Secondary

Measure	Time frame
Incidence and severity of NCI-CTCAE (Palmar-plantar erythrodysesthesia syndrome) grading by oncologist	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 17, 2026